Kerberan

Clopidogrel, the active ingredient in Kerberan, is a P2Y12 receptor antagonist (antiplatelet agent) presented as an oral tablet for oral use. It is indicated for the prevention of atherothrombotic events in patients who have experienced recent myocardial infarction, stroke, or who have established peripheral arterial disease, and for secondary prevention after acute coronary syndrome.

GNH USA supplies Kerberan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kerberan belongs to the antiplatelet drug class and is used to reduce thrombotic risk in several cardiovascular conditions.

- Myocardial infarction: lowers the chance of recurrent atherothrombotic events after a recent heart attack. - Ischemic stroke: helps prevent subsequent strokes in patients with a prior cerebrovascular event. - Peripheral arterial disease: reduces limb‑related thrombotic complications in patients with established disease. - Acute coronary syndrome: provides secondary prevention of cardiovascular events following unstable angina or non‑ST‑segment elevation myocardial infarction.

Kerberan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bleeding gums or easy bruising - Diarrhea or abdominal discomfort - Nausea or vomiting - Headache or dizziness

Serious or Rare Side Effects: - Severe or uncontrolled bleeding - Thrombotic thrombocytopenic purpura (TTP) - Hepatic dysfunction or jaundice

Before prescribing Kerberan, clinicians should evaluate individual risk factors and monitor patients appropriately.

- Assess bleeding risk: review history of hemorrhage, surgery, or anticoagulant use. - Monitor platelet function: consider testing in patients with suspected resistance. - Adjust for hepatic impairment: use caution in patients with liver disease. - Avoid in active pathological bleeding: discontinue if severe bleeding occurs. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Kerberan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CYP2C19 inhibitors (e.g., omeprazole): may reduce antiplatelet effect. - Strong CYP3A4 inducers (e.g., rifampin): may lower plasma concentrations. - Concurrent anticoagulants (e.g., warfarin, heparin): increase risk of major bleeding.

Moderate Interactions (Monitor Closely): - NSAIDs or aspirin: may exacerbate gastrointestinal bleeding. - SSRIs or SNRIs: can increase bleeding tendency. - Proton pump inhibitors (e.g., esomeprazole): may modestly affect clopidogrel activation.